Intervention: Monoclonal antibodies

Orth

Germany
|
2022-2023
  • Adults
  • Elderly
  • Fragile population
  • Hospital wide
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab
  • Molnupiravir
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Pinchera

Italy
|
2023-2023
  • Adults
  • Elderly
  • Fragile population
  • Infectious diseases unit
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Tixagevimab/Cilgavimab

Colaneri

Italy
|
2021-2023
  • Adults
  • Elderly
  • Fragile population
  • Hospital wide
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab
  • Molnupiravir
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab
  • Bamlanivimab/ Etesevimab

Huygens

The Netherlands
|
2021-2022
  • Adults
  • Elderly
  • Fragile population
  • Immunocompromised host
  • Hospital wide
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Palčić Marija

Croatia
|
2021-2022
  • Adults
  • Elderly
  • Hospital wide
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Tocilizumab

Gentile

Italy
|
2023-2023
  • Adults
  • Elderly
  • Fragile population
  • Immunocompromised host
  • Hospital wide
  • Infectious diseases unit
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab

Gentile

Italy
|
2023-2023
  • Adults
  • General population
  • Elderly
  • Fragile population
  • Hospital wide
  • Emergency department
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab

Pinargote-Celorio

Spain
|
2022-2022
  • Adults
  • Elderly
  • Fragile population
  • Immunocompromised host
  • Hospital wide
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab

Nguyen

France
|
2021-2022
  • Adults
  • Fragile population
  • Immunocompromised host
  • Hospital wide
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Tixagevimab/Cilgavimab

Rotundo

Italy
|
2022-2023
  • Adults
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab
  • Molnupiravir
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Drysdale

United Kingdom
|
2022-2022
  • Adults
  • Elderly
  • Fragile population
  • Primary care
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab
  • Molnupiravir

Perrotta

Italy
|
2021-2022
  • Adults
  • General population
  • Elderly
  • Fragile population
  • Hospital wide
  • Emergency department
  • Infectious diseases unit
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab
  • Bamlanivimab/ Etesevimab